HALO:NSD-Halozyme Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 58.16

Change

+1.52 (+2.68)%

Market Cap

USD 7.22B

Volume

1.34M

Analyst Target

USD 33.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-7.62 (-1.62%)

USD 119.56B
REGN Regeneron Pharmaceuticals Inc

-6.64 (-0.63%)

USD 114.65B
ALNY Alnylam Pharmaceuticals Inc

-4.51 (-1.63%)

USD 35.44B
ARGX argenx NV ADR

+2.72 (+0.50%)

USD 32.73B
MRNA Moderna Inc

-0.77 (-1.20%)

USD 25.27B
BGNE BeiGene Ltd

+2.62 (+1.13%)

USD 24.38B
RPRX Royalty Pharma Plc

-0.14 (-0.49%)

USD 16.72B
UTHR United Therapeutics Corporatio..

-5.36 (-1.50%)

USD 15.95B
SMMT Summit Therapeutics PLC

-0.56 (-2.79%)

USD 15.35B
PCVX Vaxcyte Inc

-1.29 (-1.12%)

USD 14.00B

ETFs Containing HALO

ROYL:AU BetaShares Global Royalti.. 4.63 % 0.00 %

-0.01 (0.00%)

N/A
ETLI:XETRA L&G Pharma Breakthrough U.. 3.35 % 0.00 %

+0.06 (+0.00%)

USD 0.02B
BIOT:SW L&G Pharma Breakthrough U.. 3.12 % 0.00 %

+0.05 (+0.00%)

N/A
HLTH:AU VanEck Global Healthcare .. 2.95 % 0.00 %

-0.08 (0.00%)

USD 0.06B
FSCC Federated Hermes ETF Trus.. 1.84 % 0.00 %

-0.05 (0.00%)

N/A
SCDS JPMorgan Fundamental Data.. 1.49 % 0.00 %

-0.07 (0.00%)

N/A
VRTGX Vanguard Russell 2000 Gro.. 0.59 % 0.00 %

+0.43 (+0.00%)

USD 1.19B
VTWG Vanguard Russell 2000 Gro.. 0.59 % 0.20 %

+0.39 (+0.00%)

USD 1.02B
AGED:SW iShares Ageing Population.. 0.57 % 0.00 %

-0.07 (0.00%)

N/A
RTWO:LSE L&G Russell 2000 US Small.. 0.47 % 0.00 %

+0.30 (+0.00%)

USD 0.15B
RTWP:LSE Legal & General UCITS ETF.. 0.47 % 0.00 %

+5.00 (+0.00%)

USD 0.15B
ETLZ:XETRA L&G Russell 2000 US Small.. 0.47 % 0.00 %

+0.30 (+0.00%)

USD 0.09B
R2SC:LSE SPDR® Russell 2000 US Sm.. 0.30 % 0.00 %

+0.14 (+0.00%)

USD 3.31B
R2US:LSE SPDR® Russell 2000 US Sm.. 0.30 % 0.00 %

+0.08 (+0.00%)

USD 3.31B
R2US:PA SSgA SPDR ETFs Europe II .. 0.30 % 0.00 %

+0.24 (+0.00%)

USD 3.34B
ZPRR:F SSgA SPDR ETFs Europe II .. 0.30 % 0.00 %

N/A

USD 2.91B
ZPRR:XETRA SPDR® Russell 2000 US Sm.. 0.30 % 0.00 %

+0.11 (+0.00%)

USD 2.91B
XRSG:LSE Xtrackers Russell 2000 UC.. 0.30 % 0.00 %

+41.00 (+0.00%)

USD 1.38B
XRSU:LSE Xtrackers Russell 2000 UC.. 0.30 % 0.00 %

+0.84 (+0.00%)

USD 1.38B
XRS2:F Xtrackers (IE) Public Lim.. 0.30 % 0.00 %

+0.75 (+0.00%)

USD 1.19B
XRS2:XETRA Xtrackers Russell 2000 UC.. 0.30 % 0.00 %

+1.00 (+0.00%)

USD 1.19B
XRS2:SW Xtrackers Russell 2000 UC.. 0.30 % 0.00 %

+1.90 (+0.00%)

USD 1.38B
RSSL Global X Funds 0.30 % 0.00 %

N/A

N/A
VRTIX Vanguard Russell 2000 Ind.. 0.29 % 0.00 %

-0.31 (0.00%)

USD 10.02B
VTWO Vanguard Russell 2000 Ind.. 0.29 % 0.15 %

-0.14 (0.00%)

USD 11.71B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

+0.48 (+0.00%)

N/A
GSC Goldman Sachs ETF Trust 0.00 % 1.25 %

-0.03 (0.00%)

N/A
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

+0.61 (+0.00%)

N/A
PSC Principal U.S. Small-Cap .. 0.00 % 0.38 %

-0.14 (0.00%)

USD 0.65B
AGED:LSE iShares Ageing Population.. 0.00 % 0.00 %

-0.02 (0.00%)

N/A
AGES:LSE iShares IV Public Limited.. 0.00 % 0.00 %

+2.00 (+0.00%)

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

+2.40 (+0.00%)

N/A
URTY ProShares UltraPro Russel.. 0.00 % 0.95 %

-0.19 (0.00%)

USD 0.46B
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

-0.01 (0.00%)

N/A
IBBJ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 57.36% 85% B 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 57.36% 85% B 91% A-
Trailing 12 Months  
Capital Gain 56.18% 75% C 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.18% 75% C 85% B
Trailing 5 Years  
Capital Gain 270.21% 90% A- 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 270.21% 90% A- 93% A
Average Annual (5 Year Horizon)  
Capital Gain 28.44% N/A N/A 83% B
Dividend Return 28.44% N/A N/A 83% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 51.24% N/A N/A 35% F
Risk Adjusted Return 55.50% N/A N/A 82% B
Market Capitalization 7.22B 97% N/A 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.